EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.347
https://www.valueinhealthjournal.com/article/S1098-3015(24)00462-5/fulltext
Title :
EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00462-5&doi=10.1016/j.jval.2024.03.347
First page :
Section Title :
Open access? :
No
Section Order :
11693